Tina Tan’s Post

View profile for Tina Tan, graphic

Key takeaway [for me] so far from this morning’s panel on how to balance patient-centric #digitaltherapeutics with scalable profitability can be summarised by the phrase “Build and they will come”. If you build a product that is intrinsically engaging and keeps patient adherent to the programme, then the clinical outcomes will show themselves, product value can be seen, and uptake will come and with it the money. And how to make a product engaging? For Hannes Klöpper of HelloBetter , it’s about getting patients involved as much as possible in the product development, get their feedback, use it to make necessary tweaks to improve the technology . No brainer? Are DTx companies already doing this? Other insights from Marek Ostrowski of Prosoma Kamran Adle Christian Lautner LSX - partnering for Life Science eXecutives #lsxworldcongress Laura Wamprecht

  • No alternative text description for this image
Eliane Boucher, PhD

Digital Health | Evidence Generation | Research Strategy | People Leader | Science Communicator | Behavioral Science | Recovered Academic

2mo

If DTx companies are doing this, they mostly aren’t talking about it… but I suspect most are not listening to the user/patients enough. We’ve seen research and science budgets get slashed with budget cuts and layoffs, along with UX researchers - but these are going to be critical to improving engagement, which is the KPI we should all be chasing.

To view or add a comment, sign in

Explore topics